A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules

Inclusion Criteria Patients must be: Normal, healthy, HIV-negative adults who fully comprehend the purpose and details of the study. Available for 1 year of follow-up. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: They or their sexual partners have identifiable high-risk behavior for HIV infection. Positive syphilis serology (e.g., VDRL). Positive for circulating hepatitis B antigen. Patients with the following prior conditions are excluded: History of positive PPD (tuberculin test). History of immunodeficiency or chronic illness. Evidence of depression or under treatment for psychiatric problems during the past year. Prior Medication: Excluded: Immunosuppressive medications. Prior Treatment: Excluded: Blood transfusions or cryoprecipitates within the past 6 months. Risk Behavior: Excluded: High-risk behavior for HIV infection. History of intravenous drug use. More than one sexual partner in the last 6 months. Syphilis, gonorrhea, or any other sexually transmitted diseases (including chlamydia or pelvic inflammatory disease) in the past 6 months.